➤ FDA approves next-generation phaco machine ➤ Study: Endogenous compound reduces glaucomatous vision loss independent of IOP ➤ Successful transplant of stem cell-derived retinal ganglion cells in lab ➤ Phase 2 clinical trial for intravitreal dexamethasone implant ➤ ASCRS events
➤ NDA filed for topical glaucoma and ocular hypertension ophthalmic solution ➤ Nepafenac vs. placebo, results from Phase 2 study ➤ Enrollment completed for photobiomodulation treatment trial ➤ ASCRS activity updates
➤ 2021 ASCRS Annual Meeting update ➤ FDA approves new monofocal IOL ➤ First patient dosed in Phase 2 trial for investigational DED therapy ➤ Phase 2a trial initiated for add-on wet AMD therapy
➤ Topline results from Phase 3 studies for nAMD treatment ➤ Phase 2 trial of betamethasone treatment for cataract surgery pain and inflammation ➤ Fast Track designation given to therapy seeking to treat achromatopsia ➤ Topline data from Phase 1 trial of travoprost intracameral implant ➤ ASCRS Journal Club
➤ Enrollment complete for Phase 3 studies of investigational dry eye drug ➤ Update from two Glaukos trials ➤ Study: Remote monitoring with implantable IOP sensor affects clinical decision making ➤ ASCRS events
➤ Success with first-in-human implant of new artificial cornea ➤ Launch of first longitudinal study for home OCT ➤ Enrollment complete for study evaluating treatment for Leber congenital amaurosis 10 ➤ Phase 1/2a trial for wet AMD treatment with suprachoroidal injection begins enrollment ➤ Fast Track designation issued for investigational dry AMD therapy
➤ Commercial launch of Alcon’s Vivity IOL ➤ Topline results from Phase 2 trial for treatment of contact lens discomfort ➤ Company registers new artificial intelligence visual field exam device with FDA ➤ Positive Phase 3 results for faricimab for DME ➤ Research begins to create a MIGS patient-reported outcomes instrument ➤ ASCRS events